Cover Image
市場調查報告書

短腸症候群:開發中產品分析

Short Bowel Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 362375
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
短腸症候群:開發中產品分析 Short Bowel Syndrome - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 54 Pages
簡介

本報告提供短腸症候群治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

短腸症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

短腸症候群:企業開發中的治療藥

短腸症候群:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

短腸症候群:企業開發中的產品

短腸症候群的治療藥的開發企業

  • Ardelyx, Inc.
  • Medgenics, Inc.
  • Naia Limited
  • Nutrinia Ltd.
  • OxThera AB
  • Sancilio & Company, Inc.
  • Shire Plc
  • Tasly Pharmaceutical Group Co., Ltd.
  • Zealand Pharma A/S

短腸症候群:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

短腸症候群:最近的開發平台趨勢

短腸症候群:暫停中的計劃

短腸症候群:開發中止的產品

短腸症候群:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9425IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 1, 2 and 6 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Short Bowel Syndrome - Overview
  • Short Bowel Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Short Bowel Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Short Bowel Syndrome - Companies Involved in Therapeutics Development
  • Ardelyx Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Naia Ltd
  • Nutrinia Ltd
  • OxThera AB
  • Sancilio & Company Inc
  • Shire Plc
  • Tasly Pharmaceutical Group Co Ltd
  • Zealand Pharma AS
  • Short Bowel Syndrome - Drug Profiles
  • exenatide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • glepaglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GXG-8 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HM-15910 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • melatonin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NB-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NTRA-9620 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oxabact - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RDX-98940 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SC-403 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Short Bowel Syndrome - Dormant Projects
  • Short Bowel Syndrome - Discontinued Products
  • Short Bowel Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
  • Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
  • Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome
  • Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
  • May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
  • Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
  • Oct 20, 2015: Naia Rare Diseases a subsidiary of Naia, Receives Orphan Drug Designation From U.S. FDA For NB1001 For The Treatment Of Short Bowel Syndrome
  • Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome
  • Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
  • Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
  • Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
  • Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS
  • Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
  • Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome
  • Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Short Bowel Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2017
  • Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2017
  • Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2017
  • Short Bowel Syndrome - Pipeline by OxThera AB, H1 2017
  • Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2017
  • Short Bowel Syndrome - Pipeline by Shire Plc, H1 2017
  • Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2017
  • Short Bowel Syndrome - Dormant Projects, H1 2017
  • Short Bowel Syndrome - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Short Bowel Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top